Di Zhe Pharmaceutical (688192.SH) announced its performance for the first half of the year, with a net loss attributable to the parent company of 377 million yuan.

Zhimedia Finance News App, Dezhai Pharmaceutical (688192.SH) released its 2025 interim report, during the reporting period, the company achieved operating income of 355 million yuan, a year-on-year increase of 74.40%. The net loss attributable to the shareholders of the listed company was 377 million yuan, and the net loss attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 419 million yuan, with a basic loss per share of 0.87 yuan.